(AUGUST 3, 2023) At the 2023 International Mesothelioma Interest Group (iMig) conference in June, Brian Cunniff, Ph.D., assistant professor of pathology, presented early experience with “an exciting new therapeutic option for patients suffering with mesothelioma” to a global audience of clinicians, scientists, and allied professionals, according to Business Wire.
Brian Cunniff, Ph.D., assistant professor of pathology and laboratory medicine and chief science officer for RS Oncology
(AUGUST 3, 2023) At the 2023 International Mesothelioma Interest Group (iMig) conference hosted in Lille, France, in June, Brian Cunniff, Ph.D., assistant professor of pathology and laboratory medicine and chief science officer for RS Oncology (RSO), presented early experience with “an exciting new therapeutic option for patients suffering with mesothelioma” to a global audience of clinicians, scientists, and allied professionals, according to Business Wire.
“RSO-021 is an exciting new therapeutic option for patients suffering with mesothelioma,” Cunniff said. “RSO-021 exploits a universal vulnerability of tumor cells through a novel mechanism of action, leaving tumor cells unable to clear toxic waste products. We are excited to see our laboratory findings translated to patients in collaboration with RS Oncology.”
Watch a short clip from the symposium in which Dr. Cunniff explains the discovery of PRX3 and its role in cancer tumors.
Read full story
at
Business Wire